Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

VHL antibody (AA 6-175)

VHL Reactivity: Rat WB, IHC, IP, ICC Host: Rabbit Polyclonal unconjugated
Catalog No. ABIN1872243
  • Target See all VHL Antibodies
    VHL (Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL))
    Binding Specificity
    • 16
    • 15
    • 9
    • 5
    • 5
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 6-175
    Reactivity
    • 60
    • 37
    • 35
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    Rat
    Host
    • 65
    • 11
    • 2
    Rabbit
    Clonality
    • 70
    • 8
    Polyclonal
    Conjugate
    • 40
    • 5
    • 3
    • 3
    • 3
    • 3
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    This VHL antibody is un-conjugated
    Application
    • 45
    • 27
    • 26
    • 26
    • 19
    • 17
    • 12
    • 9
    • 6
    • 3
    • 3
    • 2
    • 1
    Western Blotting (WB), Immunohistochemistry (IHC), Immunoprecipitation (IP), Immunocytochemistry (ICC)
    Purpose
    Polyclonal Antibody to Von Hippel Lindau Tumor Suppressor (vHL)
    Specificity
    The antibody is a rabbit polyclonal antibody raised against vHL. It has been selected for its ability to recognize vHL in immunohistochemical staining and western blotting.
    Cross-Reactivity
    Mouse
    Purification
    Antigen-specific affinity chromatography followed by Protein A affinity chromatography
    Immunogen
    Recombinant Von Hippel Lindau Tumor Suppressor (vHL) corresdonding to Ala6~Gln175
    Isotype
    IgG
    Top Product
    Discover our top product VHL Primary Antibody
  • Application Notes

    Western blotting: 0.5-2 μg/mL

    1:500-2000 Immunohistochemistry: 5-20 μg/mL

    1:50-200 Immunocytochemistry: 5-20 μg/mL

    1:50-200 Optimal working dilutions must be determined by end user.

    Comment

    The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

    Restrictions
    For Research Use only
  • Format
    Liquid
    Concentration
    Lot specific
    Buffer
    PBS, pH 7.4, containing 0.02 % Sodium azide, 50 % glycerol.
    Preservative
    Sodium azide
    Precaution of Use
    WARNING: Reagents contain sodium azide. Sodium azide is very toxic if ingested or inhaled. Avoid contact with skin, eyes, or clothing. Wear eye or face protection when handling. If skin or eye contact occurs, wash with copious amounts of water. If ingested or inhaled, contact a physician immediately. Sodium azide yields toxic hydrazoic acid under acidic conditions. Dilute azide-containing compounds in running water before discarding to avoid accumulation of potentially explosive deposits in lead or copper plumbing.
    Handling Advice
    Avoid repeated freeze-thaw cycles.
    Storage
    4 °C,-20 °C
    Storage Comment
    Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for two year without detectable loss of activity. Avoid repeated freeze-thaw cycles.
    Expiry Date
    24 months
  • Target
    VHL (Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL))
    Alternative Name
    Von Hippel Lindau Tumor Suppressor (VHL Products)
    Synonyms
    HRCA1 antibody, RCA1 antibody, VHL1 antibody, pVHL antibody, BcDNA:RH61560 antibody, CG13221 antibody, DVhl antibody, Dmel\\CG13221 antibody, Dvhl antibody, VHL antibody, d-VHL antibody, d-vhl antibody, dVHL antibody, dmVHL antibody, vhl antibody, rca1 antibody, vhl1 antibody, hrca1 antibody, zgc:158722 antibody, Vhlh antibody, von Hippel-Lindau tumor suppressor antibody, von Hippel-Lindau antibody, von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase antibody, von Hippel-Lindau disease tumor suppressor antibody, VHL antibody, Vhl antibody, vhl antibody, CpipJ_CPIJ009992 antibody
    Background
    HRCA1, RCA1, VHL1, Von Hippel-Lindau Syndrome
    Pathways
    Tube Formation, Signaling Events mediated by VEGFR1 and VEGFR2, Ubiquitin Proteasome Pathway
You are here:
Support